BMS-backed biopharma in pact with preclinical R&D experts

By Fiona Barry

- Last updated on GMT

Harvard Medical School: the alliance will help translate university discoveries into drugs
Harvard Medical School: the alliance will help translate university discoveries into drugs

Related tags: Pharmacology, Bristol-myers squibb

A preclinical biotech backed by Bristol-Myers Squibb is forming a strategic alliance with Synergy Partners R&D Solutions to boost academic discoveries.

Allied-Bristol Life Sciences, a drug discovery JV founded by BMS and venture capitalists Allied Minds in August, announced Synergy will offer R&D advice and scientific support.

Synergy, founded by ex-Schering-Plough execs, provides drug development services for pharma clients in medicinal chemistry, process chemistry, pharmacology, metabolism, toxicology, and drug safety.

The staff of twenty includes ex-employees of BMS, Merck & Co., AstraZeneca, Pfizer, Johnson & Johnson, and Eli Lilly.

The latest alliance will concentrate on preclinical drug discovery of biopharmaceuticals.

Allied-Bristol was set up to speed along innovations made by US academic research institutions. The enterprise, running since this summer, identifies early-stage and preclinical research at leading universities and allows selected academic teams to access BMS’s drug discovery expertise and Allied Minds’ financial and management experience.

Allied Minds and Bristol-Myers Squibb said they plan to form and fund together new companies to conduct feasibility and full-phase discovery programs.

Once a program succeeds in identifying a preclinical candidate, Bristol-Myers Squibb will have the option to acquire the company from Allied-Bristol Life Sciences under pre-agreed terms.

The drug development team at Synergy Partners includes leaders within the biopharmaceutical industry in diseases of high interest to Allied-Bristol Life Sciences. We are pleased to have them joining our team as we move forward with this unique opportunity to advance academic innovations to drug candidates,​” said Chris Silva, CEO of Allied Minds.

Earlier this year, Bristol-Myers Squibb announced a five-year extension​ to its strategic alliance with Syngene International, India’s largest CRO.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Planning Your Preclinical Assessment

Planning Your Preclinical Assessment

Altasciences | 17-Jan-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us

Products

View more

Webinars